SGE-102: A novel therapy for refractory status epilepticus

Epilepsia

Volumn 54, Issue SUPPL. 6, 2013, Pages 81-83

  Reddy, Kiran ^a   Reife, Ross ^a   Cole, Andrew J ^b  

^a Sage Therapeutics Inc   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticonvulsant; Clinical trial; Neurosteroid; Phase II; Randomized

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANTICONVULSIVE AGENT; MIDAZOLAM; NEUROSTEROID; PLACEBO; SGE 102; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; PROGESTERONE; SGE-102;

ADULT; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT DISEASE; REFRACTORY STATUS EPILEPTICUS; SEIZURE; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); METABOLISM; PHASE II; RANDOMIZED; REVIEW; ANALOGS AND DERIVATIVES; STATUS EPILEPTICUS;

ANTICONVULSANT; CLINICAL TRIAL; NEUROSTEROID; PHASE II; RANDOMIZED;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; PROGESTERONE; STATUS EPILEPTICUS;

EID: 84891503889     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12286     Document Type: Article

References (17)

1. Belelli D, Bolger MB, Gee KW. (1989) Anticonvulsant profile of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one. Eur J Pharmacol 166:325-329.
2. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. (2002) Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: A systematic review. Epilepsia 43:146-153.
3. Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. (2013) Predictors of outcome in refractory status epilepticus. JAMA Neurol 70:72-77.
4. Holtkamp M, Othman J, Buchheim K, Meierkord H. (2005) Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 76:534-539.
5. Kokate TG, Svensson BE, Rogawski MA. (1994) Anticonvulsant activity of neurosteroids: Correlation with gamma-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 270:1223-1229.
6. Kokate TG, Cohen AL, Karp E, Rogawski MA. (1996) Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 35:1049-1056.
7. Kokate TG, Yamaguchi S, Pannell LK, Rajamani U, Carroll DM, Grossman AB, Rogawski MA. (1998) Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice. J Pharmacol Exp Ther 287:553-558.
8. Lonsdale D, Burnham WM. (2007) The anticonvulsant effects of allopregnanolone against amygdala-kindled seizures in female rats. Neurosci Lett 411:147-151.
9. Lossin C. (2012) Allopregnanolone treatment in a rat pediatric status epilepticus model: Comparison with diazepam 2012 American Epilepsy Society Annual Meeting, AES.
10. Lowenstein DH, Alldredge BK. (1993) Status epilepticus at an urban public hospital in the 1980s. Neurology 43:483-488.
11. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. (2002) Refractory status epilepticus: Frequency, risk factors, and impact on outcome. Arch Neurol 59:205-210.
12. Naylor DE, Liu H, Wasterlain CG. (2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25:7724-7733.
13. Reddy DS, Rogawski MA. (2012) Neurosteroids - endogenous regulators of seizure susceptibility and role in the treatment of epilepsy. In Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (Eds) Jasper's basic mechanisms of the epilepsies. Oxford University Press, New York, pp. 984-1002.
14. Rossetti AO, Logroscino G, Bromfield EB. (2005) Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. Arch Neurol 62:1698-1702.
15. Rossetti AO, Milligan TA, Vulliemoz S, Michaelides C, Bertschi M, Lee JW. (2011) A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 14:4-10.
16. Shorvon S, Ferlisi M. (2011) The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain 134:2802-2818.
17. Sutter R, Marsch S, Fuhr P, Ruegg S. (2013) Mortality and recovery from refractory status epilepticus in the intensive care unit: A 7-year observational study. Epilepsia 54:502-511.